文献速递核素与放射性配体治疗

177Lu-PSMA-617 治疗中的辐射剂量学

Radiation Dosimetry in 177Lu-PSMA-617 Therapy.
PubMed 文献 · Semin Nucl Med · 2021-12-08

本文综述了177Lu-PSMA-617治疗中辐射剂量学的应用现状与挑战,涉及正常器官剂量估算、肿瘤剂量学意义、个体化剂量分析及不同剂量测定方法,并指出剂量学未纳入TheraP或VISION随机研究。

要点

  • 177Lu-PSMA-617在去势抵抗转移性前列腺癌中显示疗效与生存获益。
  • 常见低级别毒性如恶心、口干、血细胞减少难以通过剂量学预测。
  • 肿瘤剂量学可能有助于早期预测治疗失败并指导个体化治疗。

核心结论

  • 177Lu-PSMA-617治疗中正常器官剂量范围已逐渐明确,但剂量学未纳入TheraP或VISION随机研究,常规临床应用存在困难。
  • 肿瘤剂量学及个体化辐射分析可能有助于优化治疗,但需进一步研究。

研究设计与样本

  • 综述,总结177Lu-PSMA-617治疗的剂量学及临床文献。

主要发现

  • 常见低级别毒性如恶心、口干和血细胞减少不能基于剂量学估算轻易预测。
  • 177Lu-PSMA-617在正常组织中保留模式相对一致,对转移性前列腺癌表型具有高特异性。
  • 肾脏、唾液腺和骨髓的人群剂量学已有广泛报道,典型剂量范围正逐渐建立。
  • 个体间肿瘤和正常器官摄取存在变异性,为基于潜在毒性阈值或肿瘤控制的个体化辐射分析提供依据。
  • 剂量测定可采用平面、三维SPECT或混合数据集,可靠测量可通过任一方法获得,但计算分析发展更适合全三维成像。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radionuclide therapy using the small molecule PSMA bound to the beta-emitting radionuclide, Lutetium-177 (177Lu-PSMA) has demonstrated efficacy and survival benefit castrate resistant metastatic disease and represents a novel new line of therapy. Whilst dosimetry was critical for early development, it was not incorporated into either the TheraP or VISION randomized studies, highlighting the difficulty of adopting dosimetry in routine clinical practice. Accumulated clinical experience has also shown that the common (and generally low grade) toxicities such as nausea, xerostomia, and cytopenias are not readily predicted on the basis of dosimetry estimates. The majority of dosimetry and clinical literature deals with the radiopharmaceutical 177Lu-PSMA-617 which displays relatively consistent patterns of retention among normal tissues and high specificity for metastatic prostate cancer phenotypes. Population dosimetry incorporating estimates to the kidneys, salivary glands, and bone marrow have been widely reported the typical range of doses is becoming well established. There is growing interest on tumor dosimetry in 177Lu-PSMA-617 therapy as an overall modest side-effect profile from primary organ retention has been observed. A focus away from normal organ dosimetry to whole body tumor dosimetry may enable early prediction of treatment failure. Given the safety of 177Lu-PSMA there is also potential to escalate administered radioactivity to further improve outcomes. Importantly, the variability of uptake between individuals, both to tumor and normal organs, has also been highlighted which provides some rationale for the utility of personalized radiation analysis to optimize treatment based on potential toxicity thresholds or tumor control. Methods to perform dosimetry using serial post treatment imaging may incorporate planar, 3D SPECT, or hybrid datasets. Reliable measurements may be obtained through either method, however, continued developments in computational analysis are better suited to fully 3D imaging; particularly in conjunction with volumetric CT to assist with alignment and contouring. Dose analysis over sequential treatment cycles is vital to understand the radiobiology of these treatments which is unique compared to external beam therapy due to dose rate, fractionation scheme, and potential for intratumoral nonuniformity.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jackson P, Hofman M, McIntosh L, et al. Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Semin Nucl Med. 2021. PMID: 34893320. doi:10.1053/j.semnuclmed.2021.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。